Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2003 Aug;24(8):402-8.

Animal models of stroke: do they have value for discovering neuroprotective agents?

Author information

  • 1AstraZeneca R&D Charnwood, Loughborough LE11 5RH, UK. richard.green@astrazeneca.com

Abstract

There has been a series of high-profile failures of drugs in clinical trials of acute ischaemic stroke that were designed to meet criteria necessary for drug regulatory approval. This has, again, called into question the value of animal models for identifying effective neuroprotective agents. Here, we review evidence that physiological changes (reperfusion, hyperglycaemia, hypothermia and blood pressure) produce comparable changes in outcome in both animal models and human stroke patients, which indicates that the models should identify clinically effective neuroprotective agents. We suggest that most clinical failures have occurred because compounds were administered differently in animal and clinical studies. We review earlier guidelines on the information that is necessary from preclinical studies before a compound enters clinical trials, and propose modifications to these guidelines.

PMID:
12915049
DOI:
10.1016/S0165-6147(03)00192-5
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center